DAF as a Therapeutic Target for Steroid Hormones: Implications for Host–Pathogen Interactions

  • Bogdan NowickiEmail author
  • Stella Nowicki
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 735)


In this chapter, we present a concise historic prospective and a summary of accumulated knowledge on steroid hormones, DAF expression, and therapeutic implication of steroid hormone treatment on multiple pathologies, including infection and the host–pathogen interactions. DAF/CD55 plays multiple physiologic functions including tissue protection from the cytotoxic complement injury, an anti-inflammatory function due to its anti-adherence properties which enhance transmigration of monocytes and macrophages and reduce tissue injury. DAF physiologic functions are essential in many organ systems including pregnancy for protection of the semiallogeneic fetus or for preventing uncontrolled infiltration by white cells in their pro- and/or anti-inflammatory functions. DAF expression appears to have multiple regulatory tissue-specific and/or menstrual cycle-specific mechanisms, which involve complex signaling mechanisms. Regulation of DAF expression may involve a direct or an indirect effect of at least the estrogen, progesterone, and corticosteroid regulatory pathways. DAF is exploited in multiple pathologic conditions by pathogens and viruses in chronic tissue infection processes. The binding of Escherichia coli bearing Dr adhesins to the DAF/CD55 receptor is DAF density dependent and triggers internalization of E. coli via an endocytic pathway involving CD55, lipid rafts, and microtubules. Dr+ E. coli or Dr antigen may persist in vivo in the interstitium for several months. Further understanding of such processes should be instrumental in designing therapeutic strategies for multiple conditions involving DAF’s protective or pathologic functions and tailoring host expression of DAF.


Nitric Oxide Paroxysmal Nocturnal Hemoglobinuria Endometrial Adenocarcinoma Blood Group Antigen Decay Accelerate Factor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Akira S (2003) Toll-like receptor signaling. J Biol Chem 278:38105–38108CrossRefGoogle Scholar
  2. Anderson GG, Palermo JJ, Schillin JD, Roth R, Heuser J, Hultgren SJ (2003) Intracellular bacterial biofilm-like pods in urinary tract infections. Science 301:105–107CrossRefGoogle Scholar
  3. Andoh A, Fujiyama Y, Sumiyoshi K, Sakumoto H, Okabe H, Bamba T (1997) Tumour necrosis factor-alpha up-regulates decay-accelerating factor gene expression in human intestinal epithelial cells. Immunology 90:358–363CrossRefGoogle Scholar
  4. Bergelson JM, Chan M, Solomon KR, St John NF, Lin H, Finberg RW (1994) Decay-accelerating factor (CD55), a glycosylphosphatidylinositol-anchored complement regulatory protein, is a receptor for several echoviruses. Proc Natl Acad Sci USA 91:6245–6249CrossRefGoogle Scholar
  5. Bergelson JM, Mohanty JG, Crowell RL, St John NF, Lublin DM, Finberg RW (1995) Coxsackievirus B3 adapted to growth in RD cells binds to decay-accelerating factor (CD55). J Virol 69:1903–1906PubMedPubMedCentralGoogle Scholar
  6. Curran E, Tassell AH, Judy BM, Nowicki B, Montgomery-Rice V, Estes DM, Nowicki S (2007) Estrogen increases menopausal host susceptibility to experimental ascending urinary tract infection. J Infect Dis 195:680–683CrossRefGoogle Scholar
  7. Fang L, Nowicki B, Yallampalli C (2001) Differential expression of uterine nitric oxide system in pregnant and nonpregnant rats with intrauterine bacterial infection. Am J Physiol Regul Integr Comp Physiol 280:R1356–R1363CrossRefGoogle Scholar
  8. Fang L, Nowicki BJ, Urvil P, Goluszko P, Nowicki S, Young SL, Yallampalli C (2004) Epithelial invasion by Escherichia coli bearing Dr fimbriae is controlled by nitric oxide-regulated expression of CD55. Infect Immun 72:2907–2914CrossRefGoogle Scholar
  9. Goluszko P, Moseley S, Truong LD, Kaul A, Nowicki S, Nowicki B (1997) Development of experimental model of chronic pyelonephritis with Escherichia coli O75:K5:H- bearing Dr fimbriae: mutation in the dra region prevented tubulointerstitial nephritis. J Clin Invest 99:1–11CrossRefGoogle Scholar
  10. Hart A, Nowicki BJ, Reisner B, Pawelczyk E, Goluszko P, Urvil P, Anderson G, Nowicki S (2001) Ampicillin-resistant Escherichia coli in gestational pyelonephritis: increased occurrence and association with the colonization factor Dr adhesin. J Infect Dis 183:1526–1529CrossRefGoogle Scholar
  11. Hoffmann EM (1969) Inhibition of complement by a substance isolated from human erythrocytes. I. Extraction from human erythrocyte stroma. Immunochemistry 6:391–403CrossRefGoogle Scholar
  12. Holla VR, Wang D, Brown JR, Mann JR, Katkuri S, DuBois RN (2005) Prostaglandin E2 regulates the complement inhibitor CD55/decay accelerating factor in colorectal cancer. J Biol Chem 280:476–483CrossRefGoogle Scholar
  13. Holmes CH, Simpson KL, Okada H, Okada N, Wainwright SD, Purcell DF, Houlihan JM (1992) Complement regulatory proteins at the feto-maternal interface during human placental development: distribution of CD59 by comparison with membrane cofactor protein (CD46) and decay accelerating factor (CD55). Eur J Immunol 22: 1579–1585CrossRefGoogle Scholar
  14. Kaul AK, Nowicki BJ, Martens MG, Goluszko P, Hart AR, Nagamani M, Kumar D, Pham T, Nowicki S (1994) Decay accelerating factor (DAF) is expressed in the human endometrium and may serve as the natural ligand for Dr pili of Escherichia coli. Am J Reprod Immunol 32:194–199CrossRefGoogle Scholar
  15. Kaul A, Nagamani M, Nowicki B (1995) Decreased expression of endometrial decay accelerating factor (DAF), a complement regulatory protein, in patients with luteal phase defect. Am J Reprod Immunol 34:236–240CrossRefGoogle Scholar
  16. Kaul A, Goluszko PG, Hart A, Martens M, Pham T, Nowicki S, Nowicki B (1996) Rapid cycle changes in density and accessibility of endometrial ligands for Escherichia coli Dr fimbriae. Infect Immun 64:611–615PubMedPubMedCentralGoogle Scholar
  17. Louis NA, Kong T, Hamilton KE, Colgan SP (2005a) HIF-dependent induction of apical CD55 coordinates epithelial clearance of neutrophils. FASEB J 19:950–959CrossRefGoogle Scholar
  18. Louis NA, Hamilton KE, Kong T, Colgan SP (2005b) HIF-dependent induction of apical CD55 coordinates epithelial clearance of neutrophils. FASEB J 19:950–959CrossRefGoogle Scholar
  19. Mason JC, Steinberg R, Lidington EA, Kinderlerer AR, Ohba M, Haskard DO (2004) Decay-accelerating factor induction on vascular endothelium by vascular endothelial growth factor (VEGF) is mediated via a VEGF receptor-2 (VEGF-R2)- and protein kinase C-alpha/epsilon (PKCalpha/epsilon)-dependent cytoprotective signaling pathway and is inhibited by cyclosporin A. J Biol Chem 279:41611–41618CrossRefGoogle Scholar
  20. Moulds JM, Nowicki S, Nowicki BJ, Moulds JJ (1996) Human blood groups: incidental receptors for viruses and bacteria. Transfusion 36:362–374CrossRefGoogle Scholar
  21. Nicholson-Weller A, March JP, Rosenfeld SI, Austen KF (1983) Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc Natl Acad Sci USA 80:5066–5070CrossRefGoogle Scholar
  22. Nowicki B (2002) Urinary tract infection in pregnant women: old dogmas and current concepts. Curr Infect Dis Rep 4:529–535CrossRefGoogle Scholar
  23. Nowicki B, Hull R, Moulds J (1988a) Use of the Dr hemagglutinin of uropathogenic Escherichia coli to differentiate normal from abnormal red cells in paroxysmal nocturnal hemoglobinuria. N Eng J Med 319:1289–1290CrossRefGoogle Scholar
  24. Nowicki B, Moulds J, Hull R, Hull S (1988b) A hemagglutinin of uropathogenic E. coli recognized the Dr blood group antigen. Infect Immun 56:1057–1060PubMedPubMedCentralGoogle Scholar
  25. Nowicki B, Truong L, Moulds J, Hull R (1988c) Presence of the Dr receptor in normal human tissues and its possible role in pathogenesis of ascending urinary tract infection. Am J Pathol 133:1–4PubMedPubMedCentralGoogle Scholar
  26. Nowicki B, Fang L, Singhal S, Nowicki S, Yallampalli C (1997) Lethal outcome of uterine infection in pregnant but not in nonpregnant rats and increased death rate with inhibition of nitric oxide. Am J Reprod Immunol 38:309–312CrossRefGoogle Scholar
  27. Nowicki S, Nowicki B, Pham T, Hasan R, Nagamani M (2001) Expression of decay accelerating factor (DAF) in endometrial adenocarcinoma is inversely related to the stage of tumor. Am J Reprod Immunol 46:144–148CrossRefGoogle Scholar
  28. Nowicki S, Izban M, Pawelczyk E, Agboto V, Pratap S, Olson G, Nowicki B (2009) Preterm labor: CD55 in maternal blood leukocytes. Am J Rep Immunol 61:360–367CrossRefGoogle Scholar
  29. Nowicki B, Sledzinska A, Samet A, Nowicki S (2011a) Pathogenesis of gestational UTI: urinary obstruction vs. immune adaptation and microbial virulence. BJOG 218:109–112CrossRefGoogle Scholar
  30. Nowicki S, Rana T, Singh R, Nowicki B (2011) Dexamethasone treatment downregulates DAF and decrease intracellular survival of Dr  +  E. coli in HeLa cells. In: Proceedings of the 5th international conference on complement therapeutics, abstract 18, Rhodes, 22–27 June 2011Google Scholar
  31. O’Brien DP, Israel DA, Krishna U, Romero-Gallo J, Nedrud J, Medof ME, Lin F, Redline R, Lublin DM, Nowicki BJ, Franco AT, Ogden S, Williams AD, Polk DB, Peek RM Jr (2006) The role of decay-accelerating factor as a receptor for Helicobacter pylori and a mediator of gastric inflammation. J Biol Chem 281:13317–13323CrossRefGoogle Scholar
  32. Orlander JD, Jick SS, Dean AD, Jick H (1992) Urinary tract infections and estrogen use in older women. J Am Geriatr Soc 40:817–820CrossRefGoogle Scholar
  33. Pacheco LD, Hankins GD, Costantine MM, Anderson GD, Pawelczyk E, Nowicki S, Nowicki BJ (2011) The role of human decay-accelerating factor in the pathogenesis of preterm labor. Am J Perinatol 28:565–570CrossRefGoogle Scholar
  34. Pangburn MK, Schreiber RD, Muller-Eberhard HJ (1983) Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci USA 80:5430–5434CrossRefGoogle Scholar
  35. Sartini D, Moussawi M, Sallam R, Bernstein I, Huber S (2004) Correlation between serum estradiol in the follicular phase of the ovarian cycle and decay acceleration factor (DAF) expression on red blood cells and coxsackievirus B-3 induced hemagglutination in young cycling women. Am J Reprod Immunol 51:180–187CrossRefGoogle Scholar
  36. Schreiber J, Jenner RG, Murray HL, Gerber GK, Gifford DK, Young RA (2006) Coordinated binding of NF-kB family members in the response of human cells to lipopolysaccharide. Proc Natl Acad Sci USA 103:5899–5904CrossRefGoogle Scholar
  37. Selvarangan R, Goluszko P, Popov V, Singhal J, Pham T, Lublin DM, Nowicki S, Nowicki B (2000) Role of decay-accelerating factor domains and anchorage in internalization of Dr. fimbriated Escherichia coli. Infect Immun 68:1391–1399CrossRefGoogle Scholar
  38. Śledzińska A, Mielech A, Krawczyk B, Samet A, Nowicki B, Nowicki S, Jankowski Z, Kur J (2011) Fatal sepsis in a pregnant woman with chronic pyelonephritis caused by Escherichia coli bearing Dr and P adhesins: diagnosis based on postmortem strain genotyping. BJOG 18:266–269CrossRefGoogle Scholar
  39. Song WC, Deng C, Raszmann K, Moore R, Newbold R, McLachlan JA, Negishi M (1996) Mouse decay-accelerating factor: selective and tissue-specific induction by estrogen of the gene encoding the glycosylphosphatidylinositol-anchored form. J Immunol 157:4166–4172PubMedGoogle Scholar
  40. Spiller OB, Criado-Garcia O, Rodriguez DC, Morgan BP (2000) Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack. Clin Exp Immunol 121:234–241CrossRefGoogle Scholar
  41. Yallampalli C, Izumi H, Byam-Smith M, Garfield RE (1994) An l-arginine-nitric oxide-cyclic guanosine monophosphate system exists in the uterus and inhibits contractility during pregnancy. Am J Obstet Gynecol 170:175–185PubMedGoogle Scholar
  42. Young SL, Lessey BA, Fritz MA, Meyer WR, Murray MJ, Speckman PL, Nowicki BJ (2002) In vivo and in vitro evidence suggests that HB-EGF regulates endometrial expression of human decay-accelerating factor. J Clin Endocrinol Metab 87:1368–1375CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of Obstetrics and GynecologyMeharry Medical CollegeNashvilleUSA
  2. 2.Department of Microbiology and ImmunologyMeharry Medical CollegeNashvilleUSA

Personalised recommendations